Last reviewed · How we verify

NCT02999152: BIOM-DRI

Validation of Radio-induced Damage Biomarkers

Terminated NA Last updated 22 February 2022
What this trial tests

NA trial testing blood and urines samples in Bone Metastasis in 16 participants. Terminated before completion.

Timeline
22 June 2017
Primary endpoint
15 June 2020
15 June 2020

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Saint Etienne
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment16
Start date22 June 2017
Primary completion15 June 2020
Estimated completion15 June 2020
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Who can join

Adults 18 to 70, any sex, with Bone Metastasis or Malignant Hemopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to confirm in humans the relevance and the kinetics of radio-induced bio-markers in plasma and urines, previously described at the preclinical stage.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Polyphenols, the Healthy Brand of Olive Oil: Insights and Perspectives.
    Finicelli M, Squillaro T, Galderisi U, Peluso G. · · 2021 · cited 36× · PMID 34836087 · DOI 10.3390/nu13113831

Verify or expand the search:

Other recruiting trials for Bone Metastasis

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Saint Etienne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02999152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing